M. Bektas Et Al. , "HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER," European Congress of Rheumatology (EULAR) , Milan, Italy, pp.544, 2023
Bektas, M. Et Al. 2023. HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER. European Congress of Rheumatology (EULAR) , (Milan, Italy), 544.
Bektas, M., Yuce, S., Ay, M., Uyar, M., Onder, M., & Kilic, M. I., (2023). HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER . European Congress of Rheumatology (EULAR) (pp.544). Milan, Italy
Bektas, Murat Et Al. "HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER," European Congress of Rheumatology (EULAR), Milan, Italy, 2023
Bektas, Murat Et Al. "HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER." European Congress of Rheumatology (EULAR) , Milan, Italy, pp.544, 2023
Bektas, M. Et Al. (2023) . "HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER." European Congress of Rheumatology (EULAR) , Milan, Italy, p.544.
@conferencepaper{conferencepaper, author={Murat BEKTAŞ Et Al. }, title={HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER}, congress name={European Congress of Rheumatology (EULAR)}, city={Milan}, country={Italy}, year={2023}, pages={544} }